1. Приказ Минздравсоцразвития РФ от 03.12.2007 №736 “Об утверждении перечня медицинских показаний для искусственного прерывания беременности.” 2. Федеральный закон от 21.11.2011 №323-ФЗ (ред. от 27.12.2019) “Об основах охраны здоровья граждан в Российской Федерации” (с изм. и доп., вступ. в силу с 08.01.2020). (Текст : электронный // Официальный интернет-портал правовой информации. – Москва. – URL : http://www.consultant.ru/document/cons_doc_LAW_121895/). 3. Приказ Министерства здравоохранения РФ от 20 октября 2020 г. N 1130н "Об утверждении Порядка оказания медицинской помощи по профилю “акушерство и гинекология.” 4. Медикаментозное прерывание беременности Клинические рекомендации (протокол лечения). Письмо Минздрава РФ от 14.10. 2015. 5. Bettahar K., Pinton A., Boisramé T., Cavillon V., Wylomanski S., Nisand I., et al. Interruption volontaire de grossesse par voie médicamenteuse. J Gynécologie Obs Biol la Reprod. 2016; 45(10):1490–514. 6. Савельева Г.М., Сухих Г.Т. С.В.Н. Акушерство. Национальное руководство. 2-е издание. 2018. 1735 p. 7. Abortion care guideline. World Health Organization 2022, 210 p. 8. Savitz D.A., Terry J.W., Dole N., Thorp J.M., Siega-Riz A.M., Herring A.H. Comparison of pregnancy dating by last menstrual period, ultrasound scanning, and their combination. Am J Obstet Gynecol. 2002; 187(6):1660–6. 9. Neufeld L.M., Haas J.D., Grajéda R., Martorell R. Last menstrual period provides the best estimate of gestation length for women in rural Guatemala. Paediatr Perinat Epidemiol. 2006; 20(4):290–8. 10. Клинические рекомендации «Нормальная беременность» https://roagportal.ru/recommendations_obstetrics. 11. Письмо Минздрава России от 04/12/2018 №15-4/10/2-7839 “Искусственное прерывание беременности на поздних сроках по медицинским показаниям при наличии аномалий развития плода.” 12. Judd W.J., Luban N.L., Ness P.M., Silberstein L.E., Stroup M., Widmann F.K. Prenatal and perinatal immunohematology: recommendations for serologic management of the fetus, newborn infant, and obstetric patient. Transfusion. 1990; 30(2):175–83. 13. McBain R.D., Crowther C.A., Middleton P. Anti-D administration in pregnancy for preventing Rhesus alloimmunisation. Cochrane database Syst Rev. 2015; (9):CD000020. 14. Клинические рекомендации: «Резус-изоиммунизация. Гемолитическая болезнь плода»: https://roag-portal.ru/recommendations_obstetrics. 20 15. White J., Qureshi H., Massey E., Needs M., Byrne G., Daniels G., et al. Guideline for blood grouping and red cell antibody testing in pregnancy. Transfus Med. 2016; 26(4):246–63. 16. ACOG Practice Bulletin No. 192: Management of Alloimmunization During Pregnancy. Obstet Gynecol. 2018; 131(3):e82–90. 17. Муратова А.Ю. Изменение показателей тромбоэластометрии и плазменного гемостаза у женщин в акушерской практике. Кубанский научный медицинский вестник. 2017; 24(5):54–8. 18. Shi J., Cao H., Hong L., Ma J., Cui L., Zhang Y., et al. Diagnostic yield of whole exome data in fetuses aborted for conotruncal malformations. Prenat Diagn. 2022; 42(7):852–61. 19. Li C., Lyu Y., Hou R., Liu C., Li-Ling J., Li H. [Clinical feature and pathogenic analysis of a fetus with split hand-foot malformation]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2020; 37(4):462–6. 20. Nath S., Moghe M., Chowdhury A., Godbole K., Godbole G., Doiphode M., et al. Is germline transmission of MAD2 gene deletion associated with human fetal loss? Mol Hum Reprod. 2012; 18(11):554–62. 21. Queensland Clinical Guideline: Early Pregnancy Loss. 2017. 39p p. 22. Pinar M.H., Gibbins K., He M., Kostadinov S., Silver R. Early Pregnancy Losses: Review of Nomenclature, Histopathology, and Possible Etiologies. Fetal Pediatr Pathol. 2018; 37(3):191–209. 23. Royal College of Obstetricians and Gynaecologists (RCOG). The care of women requesting induced abortion. London (England): Royal College of Obstetricians and Gynaecologists (RCOG); 2011 Nov. 130 p. (Evidence-based Clinical Guideline; no. 7). http://ww. 24. Iyengar K., Paul M., Iyengar S.D., Klingberg-Allvin M., Essén B., Bring J., et al. Self-assessment of the outcome of early medical abortion versus clinic follow-up in India: a randomised, controlled, non-inferiority trial. Lancet Glob Heal. 2015; 3(9):e537–45. 25. Oppegaard K.S., Qvigstad E., Fiala C., Heikinheimo O., Benson L., GemzellDanielsson K. Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. Lancet. 2015; 385(9969):698–704. 26. Medical management of abortion. WHO, 2018, 72 p. 27. Horeau J., Bouhour J.B., Dixneuf B., Godin J.F., Horeau-godin O. [Electrocardiogram anomalies during induced abortions]. Sem Hop Paris. 1971; 47:2034–9. 28. Acharya G., Haugen M., Bråthen A., Nilsen I., Maltau J.M. Role of routine ultrasonography in monitoring the outcome of medical abortion in a clinical setting. Acta Obstet Gynecol Scand. 2004; 83(4):390–4. 21 29. Hamel C.C., van Wessel S., Carnegy A., Coppus S.F.P.J., Snijders M.P.M.L., Clark J., et al. Diagnostic criteria for retained products of conception-A scoping review. Acta Obstet Gynecol Scand. 2021; . 30. Wong S.F., Lam M.H., Ho L.C. Transvaginal sonography in the detection of retained products of conception after first-trimester spontaneous abortion. J Clin Ultrasound. 2002; 30(7):428–32. 31. Reeves M.F., Fox M.C., Lohr P.A., Creinin M.D. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. Ultrasound Obstet Gynecol. 2009; 34(1):104–9. 32. Goldberg A.B., Fortin J.A., Drey E.A., Dean G., Lichtenberg E.S., Bednarek P.H., et al. Cervical Preparation Before Dilation and Evacuation Using Adjunctive Misoprostol or Mifepristone Compared With Overnight Osmotic Dilators Alone. Obstet Gynecol. 2015; 126(3):599–609. 33. Jansen N.E., Pasker-De Jong P.C.M., Zondervan H.A. Mifepristone and misoprostol versus Dilapan and sulprostone for second trimester termination of pregnancy. J Matern Neonatal Med. 2008; 21(11):847–51. 34. Ramesh S., Roston A., Zimmerman L., Patel A., Lichtenberg E.S., Chor J. Misoprostol 1 to 3 h preprocedure vs. overnight osmotic dilators prior to early second-trimester surgical abortion. Contraception. 2015; 92(3):234–40. 35. Sagiv R., Mizrachi Y., Glickman H., Kerner R., Keidar R., Bar J., et al. Laminaria vs. vaginal misoprostol for cervical preparation before second-trimester surgical abortion: a randomized clinical trial. Contraception. 2015; 91(5):406–11. 36. Safe Abortion: Technical and Policy Guidance for Health Systems. 2nd ed. Geneva: World Health Organization; 2012. PMID: 23700650. 37. Bertholdt C., David M.G., Gabriel P., Morel O., Perdriolle-Galet E. Effect of the addition of osmotic dilators to medical induction of labor abortion: A before-and-after study. Eur J Obstet Gynecol Reprod Biol. 2020; 244:185–9. 38. Vincienne M., Anselem O., Cordier A.G., Le Ray C., Tsatsaris V., Benachi A., et al. Comparison of the Induction-to-Delivery Interval in Terminations of Pregnancy with or without Dilapan-S®. Fetal Diagn Ther. 2018; 43(1):61–7. 39. Newmann S.J., Dalve-Endres A., Diedrich J.T., Steinauer J.E., Meckstroth K., Drey E.A. Cervical preparation for second trimester dilation and evacuation. Cochrane Database Syst Rev. 2010; . 40. Shaw K.A., Shaw J.G., Hugin M., Velasquez G., Hopkins F.W., Blumenthal P.D. Adjunct mifepristone for cervical preparation prior to dilation and evacuation: a randomized trial. 22 Contraception. 2015; 91(4):313–9. 41. Lièvre M., Sitruk-Ware R. Meta-analysis of 200 or 600 mg mifepristone in association with two prostaglandins for termination of early pregnancy. Contraception. 2009; 80(1):95–100. 42. von Hertzen H., Piaggio G., Wojdyla D., Marions L., My Huong N., Tang O., et al. Two mifepristone doses and two intervals of misoprostol administration for termination of early pregnancy: a randomised factorial controlled equivalence trial*. BJOG An Int J Obstet Gynaecol. 2009; 116(3):381–9. 43. Prine L.W., MacNaughton H. Office management of early pregnancy loss. Am Fam Physician. 2011; 84(1):75–82. 44. American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 200: Early Pregnancy Loss. Obstet Gynecol. 2018; 132(5):e197–207. 45. Kim C., Barnard S., Neilson J.P., Hickey M., Vazquez J.C., Dou L. Medical treatments for incomplete miscarriage. Cochrane database Syst Rev. 2017; 1:CD007223. 46. Zhang J., Gilles J.M., Barnhart K., Creinin M.D., Westhoff C., Frederick M.M., et al. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 2005; 353(8):761–9. 47. Clinical Practice Handbook for Safe Abortion. Geneva: World Health Organization; 2014. PMID: 24624482. 48. American College of Obstetricians and Gynecologists. Practice bulletin no. 143: medical management of first-trimester abortion. Obstet. Gynecol. — 2014. — Vol. 123 (3). — Р. 676–692. 49. Best practice in comprehensive abortion care. RCOG. Best Practice Paper No. 2. — June. 2015. 50. Institute of Obstetricians and Gynaecologists, Royal College of Physicians of Ireland, Directorate of Strategy and Clinical Programmes Health Services Executive. Clinical practice guideline: The management of second trimester miscarriage. Guideline No. 29. 51. Белокриницкая Т.Е., Фролова Н.И., Белокриницкая И.А., Сухинина В.В. Сравнительная оценка клинического течения медикаментозного аборта с 200 и 600 мг мифепристона: проспективное когортное исследование. Акушерство и гинекология 2014;3:81-86. 52. Kulier R., Kapp N., Gülmezoglu A.M., Hofmeyr G.J., Cheng L., Campana A. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011; . 53. Delgado G., Davenport M.L. Progesterone Use to Reverse the Effects of 23 Mifepristone. Ann Pharmacother. 2012; 46(12):1723–1723. 54. Grossman D., White K., Harris L., Reeves M., Blumenthal P.D., Winikoff B., et al. Continuing pregnancy after mifepristone and “reversal” of first-trimester medical abortion: a systematic review. Contraception. 2015; 92(3):206–11. 55. Garratt D., Turner J. V. Progesterone for preventing pregnancy termination after initiation of medical abortion with mifepristone. Eur J Contracept Reprod Heal Care. 2017; 22(6):472–5. 56. Delgado G., Condly S.J., Davenport M., Tinnakornsrisuphap T., Mack J., Khauv V., et al. A case series detailing the successful reversal of the effects of mifepristone using progesterone. Issues Law Med. 33(1):21–31. 57. Borgatta L., Kapp N. Labor induction abortion in the second trimester. Contraception. 2011; 84(1):4–18. 58. Kapp N., Borgatta L., Stubblefield P., Vragovic O., Moreno N. Mifepristone in Second-Trimester Medical Abortion. Obstet Gynecol. 2007; 110(6):1304–10. 59. Ashok P.W., Templeton A., Wagaarachchi P.T., Flett G.M.M. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception. 2004; 69(1):51–8. 60. Gemzell-Danielsson K., Lalitkumar S. Second Trimester Medical Abortion with Mifepristone–Misoprostol and Misoprostol Alone: A Review of Methods and Management. Reprod Health Matters. 2008; 16(sup31):162–72. 61. Abortion care. NICE Guideline, 25 September 2019 www.nice.org.uk/guidance/ng140. 62. Achilles S.L., Reeves M.F. Prevention of infection after induced abortion. Contraception. 2011; 83(4):295–309. 63. Low N., Mueller M., Van Vliet H.A., Kapp N. Perioperative antibiotics to prevent infection after first-trimester abortion. Cochrane Database Syst Rev. 2012; . 64. Achilles S.L., Reeves M.F., Society of Family Planning. Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102. Contraception. 2011; 83(4):295–309. 65. Sawaya G.F., Grady D., Kerlikowske K., Grimes D.A. Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis. Obstet Gynecol. 1996; 87(5 Pt 2):884–90. 66. ACOG Committee Opinion No. 427: Misoprostol for Postabortion Care. Obstet Gynecol. 2009; 113(2, Part 1):465–8. 67. Huber D., Curtis C., Irani L., Pappa S., Arrington L. Postabortion Care: 20 Years 24 of Strong Evidence on Emergency Treatment, Family Planning, and Other Programming Components. Glob Heal Sci Pract. 2016; 4(3):481–94. 68. Tunçalp O., Gülmezoglu A.M., Souza J.P. Surgical procedures for evacuating incomplete miscarriage. Cochrane database Syst Rev. 2010; (9):CD001993. 69. Kulier R., Gülmezoglu A., Hofmeyr G., Cheng L., Campana A. Medical methods for first trimester abortion. In: Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2003. 70. National Abortion Federation. NAF Protocol for mifepristone/misoprostol in early abortion in U.S. Washington DC, USA: National Abortion Federation. — 2013. — 12 p. 71. Кан Н.Е., Тютюнник В.Л., Баранов И.И., Ганичкина М.Б., Калинина Е.А., Долгушина Н.В., Яроцкая Е.Л., Шувалова М.П., Байрамова Г.Р., Павлович С.В. – Безопасный аборт в I и II триместрах беременности в условиях стационара: Учебное пособие. – Москва: «Центр п. 72. Cheng L. Surgical versus medical methods for induced abortion during the second trimester: RHL commentary (last revised: September 28, 2011). WHO Reproductive Health Library; Geneva: World Health Organization. 73. Kelly T., Suddes J., Howel D., Hewison J., Robson S. Comparing medical versus surgical termination of pregnancy at 13-20 weeks of gestation: a randomised controlled trial. BJOG An Int J Obstet Gynaecol. 2010; 117(12):1512–20. 74. Галимова И. Р. и др. Опыт проведения прерываний беременности на поздних сроках //Практическая медицина. – 2015. – №. 4-1 (89). – С. 38-41. 75. Aaronson J., Goodman S. Obstetric anesthesia: not just for cesareans and labor. Semin Perinatol. 2014; 38(6):378–85. 76. Wortman M., Carroll K. Office-Based Gynecologic Surgery (OBGS): Past, Present, and Future: Part I. Surg Technol Int. 2019; 35:173–84. 77. Chestnut D.H., Wong C.A., Tsen L.C., Kee W.D.N., Beilin Y., Mhyre J. Chestnut’s Obstetric Anesthesia: Principles and Practice, 5th Edition. Elsevier Science; 2014. 1304 p. 78. Rahman A. Shnider and Levinson’s Anesthesia for Obstetrics, Fifth Edition. Anesthesiology. 2015; 122(1):223. 79. L.Fleisher, Wiener-Kronish J. Miller’s Anesthesia, 9th Edition. Anesthesiology. 2019; . 80. Anim-Somuah M., Smyth R.M., Jones L. Epidural versus non-epidural or no analgesia in labour. Cochrane Database Syst Rev. 2011; . 81. World Health Organization. WHO recommendations: Intrapartum care for a positive childbirth experience. Geneva; 2018. 212 p. 25 82. Медицинские критерии приемлемости для использования методов контрацепции 5-е издание, ВОЗ, 2015 г. 83. Roe A.H., Bartz D. Contraception After Surgical and Medical Abortion: A Review. Obstet Gynecol Surv. 2017; 72(8):487–93. 84. Grimes D.A., Lopez L.M., Schulz K.F., Stanwood N.L. Immediate postabortal insertion of intrauterine devices. In: Lopez LM, editor. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2010. 85. Kim C., Nguyen A.T., Berry-Bibee E., Ermias Y., Gaffield M.E., Kapp N. Systemic hormonal contraception initiation after abortion: A systematic review and meta-analysis. Contraception. 2021; 103(5):291–304.